News

  • 15 March 2017

    DSM Sinochem Pharmaceuticals Initiates Patent Litigation Against Sinopharm Weiqida Pharmaceutical

     

    DSM Sinochem Pharmaceuticals (DSP), the global leader in production and commercialization of sustainable, enzymatic antibiotics, next generation statins and anti-fungals, announced that it has filed lawsuits against Sinopharm Weiqida Pharmaceutical for patent infringement.

     

    DSM Sinochem Pharmaceuticals announced today that its wholly owned subsidiaries, DSM Sinochem Pharmaceuticals Netherlands B.V. and DSM Pharmaceuticals India Pvt. Ltd. filed lawsuits against Sinopharm Weiqida Pharmaceutical Co., LTD  ("Weiqida") for patent infringement in both the District Court of The Hague, Afdeling Handel (commercial division), Netherlands, for patent infringement of the Dutch part of European Patent Number 1,610,766 B1 and in the High Court of Delhi at New Delhi for patent infringement of Indian Patent Number 247,301. These patents, which are owned by DSP, describe and claim amoxicillin trihydrate having a low free water content and processes for the manufacture thereof.

    By its complaint, DSP seeks an injunction to prevent the infringing manufacture, use, importation and sale of Weiqida’s amoxicillin active pharmaceutical ingredient in the Netherlands and India as well as any drug product that utilizes the active pharmaceutical ingredient.

     

    Karl Rotthier, CEO at DSP said: “DSP has a world class intellectual property portfolio relating to our innovative, sustainable, and environmental friendly amoxicillin technology.  DSP will rigorously defend its IP assets worldwide as it continues to invest in its innovative R&D programs directed to enzymatic, sustainable antimicrobials and statins.”

     

    --

    About DSM Sinochem Pharmaceuticals

    DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and drug products. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.

     

    Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company active in health, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.

     

     

  • 15 March 2017

    DSM Sinochem Pharmaceuticals announces licensing agreement for intellectual property assets related to the manufacture of beta lactam antibiotics

     

    DSM Sinochem Pharmaceuticals (DSP) and Sandoz (a Novartis Division) announced today that they have executed a definitive agreement licensing certain DSP intellectual property assets for the manufacture of beta lactam antibiotics.

     

    The license agreement provides Sandoz a non-exclusive, worldwide license to certain patents including, inter alia, U.S. 8,541,199 B2 and EP 1,610,766 B1, granting freedom to operate to develop and commercialize its various beta lactam products and allows for the production of new enzymes for the sustainable manufacture of amoxicillin.

     

    Karl Rotthier, CEO of DSP stated: "DSP is pleased to have Sandoz as a licensee of our innovative, sustainable and environmentally friendly amoxicillin manufacturing technology. As part of our commitment to fight antimicrobial resistance through minimizing the environmental impact from antibiotics manufacturing, DSP is actively seeking to promote green, enzymatic routes for production of amoxicillin and other antibiotics, utilizing our patented technology. This license agreement further validates the strength of DSP’s intellectual property portfolio regarding enzymatically produced antimicrobials.”

     

    The commitment to reduce environmental impact from the production of antibiotics is also laid out in the Industry Roadmap for Progress on Combating Antimicrobial Resistance, signed by DSP, Novartis and 11 other leading pharmaceutical companies at the United Nations General Assembly in New York in September 2016.

     

    --

    About DSM Sinochem Pharmaceuticals

    DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and drug products. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.

     

    Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company active in health, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.

     

     

  • 1 January 2017

    Mr. Lu Fang Bin to join DSM Sinochem Pharmaceuticals as Chief Strategy Officer and President China

    Mr. Lu Fang Bin to join DSM Sinochem Pharmaceuticals as Chief Strategy Officer and President China

     

    Mr. Lu Fang Bin will replace Mr. Xian Ming as the Chief Strategy Officer and President China with effect from 1 January, 2017. Fang bin will be a member of the Executive Management Team and the Executive Committee (ExComm) of DSP. In this role, Fang Bin will report directly to Karl Rotthier, Chief Executive Officer.

     

    Mr. Lu has comprehensive experience in corporate management and had spent a significant period of time as General Manager of Sinochem USA based in the US. Fang Bin holds a master degree in engineering. Prior joining DSP Mr. Lu was Vice President of Sinofert Holdings Ltd. based in Beijing, China.

     

  • 2 December, 2016

    DSM Sinochem Pharmaceuticals joins the Pharmaceutical Supply Chain Initiative

    DSM Sinochem Pharmaceuticals Joins the Pharmaceutical Supply Chain Initiative to Further Drive the Goals of the UN Industry Roadmap to Combat AMR

     

    Following the signing of the UN Industry Roadmap to Combat AMR at the United Nations General Assembly in New York City in September DSM Sinochem Pharmaceuticals (DSP), the global leader in sustainable antibiotics, next generation statins and anti-fungals, has joined the Pharmaceutical Supply Chain Initiative (PSCI). The PSCI seeks to establish formal industry guidelines about ethics, labor, health and safety, environment and related management systems.

     

    DSP has been one of the driving forces in establishing the UN Industry Roadmap to Combat AMR. Joining the PSCI is a logical next step to bundle forces in the industry and establish industry wide guidelines that reach into the entire value chain to ensure antibiotics are produced responsibly and sustainably. And that the antibiotics industry does not contribute to antimicrobial resistance (AMR).

     

    The company is committed to reduce the impact that the production of antibiotics can have on the environment by further promoting the three basic measures for clean production: use the best available technology, operate dedicated wastewater treatment plants in combination with antimicrobial activity testing at all sites. DSP also believes that reducing the prevalence of substandard and counterfeit antibiotics in high-risk markets is one of the key areas in which the industry can and should take rapid action.

     

  • 21 December 2016

    Dimitri de Vreeze to join Board of DSM Sinochem Pharmaceuticals

    Dimitri de Vreeze to join Board of DSM Sinochem Pharmaceuticals

     

    On 1 February, 2017, Mr. Dimitri de Vreeze, member of the Managing Board and Executive Committee of Royal DSM N.V. will be joining the Board of Directors of DSM Sinochem Pharmaceuticals. Dimitri joins the Board following the departure of Mr. Stefan Tanda.

     

  • 23 November 2016

    Change in Board Members as per February 2017

    Change in Board Members as per February 2017

     

    Mr. Stefan Tanda, Board of DSM Sinochem Pharmaceuticals since June 2015, will step down from his position as a Managing Board Member of DSM and as such also cease to be a Board member of DSM Sinochem Pharmaceuticals. The responsibilities of Stephan Tanda will be re-arranged among the Managing Board and Executive Committee members of DSM.

     

    As of 1 February 2017 Stephan will be appointed as President and CEO of the AptarGroup, Inc. [NYSE: ATR], a global leader in innovative dispensing and sealing solutions. The AptarGroup is based in the USA and reported about €2 billion sales over 2015.

     

    His successor on the Board of DSM Sinochem Pharmaceuticals will be announced in due time.

     

    Read the full press release from DSM here.

     

  • 22 November 2016

    DSM Sinochem Pharmaceuticals Celebrates 15 Years of Green 7-ADCA Production

    Saving more than lives alone

     

    DSM Sinochem Pharmaceuticals (DSP) has achieved a significant milestone. At end of October 2016, DSP’s facility in Delft, the Netherlands, celebrated 15 years of sustainable production of 7-ADCA, the key intermediate for cephalosporin APIs. In this time period, using its breakthrough production method, DSP has contributed to more than 2.5 billion patient treatments and to a better planet by a significant reduction of CO2 emissions as well as preventing the release of antimicrobial active ingredients into the environment.

     

    DSP has produced 7-ADCA, the key intermediate for making its sustainable cephalosporin APIs including cephalexin, cefadroxil and cefradine, at Delft since 1973, and is the only remaining producer of this intermediate in the Western hemisphere. In the early 2000s, the company revolutionized the industry by introducing a new breakthrough process for the sustainable production of high-quality 7-ADCA. To this date, this process based on proprietary technology is the only combined fermentative and enzymatic route for manufacturing 7-ADCA worldwide.

     

    DSP’s mission is to provide high-quality and reliable products for people in need of healthcare. Antibiotics save lives every day and enable medical procedures that would be otherwise life-threatening. Therefore, DSP is proud that during the 15 years of green 7-ADCA production it has contributed to more than 2.5 billion cephalosporin patient treatments.

     

    As a leader in sustainable production of antibiotics, DSP has implemented the cleanest production technology available and installed dedicated wastewater treatment plants. These operate all year around as an integral part of DSP’s manufacturing process at Delft and all other sites, in combination with antimicrobial activity testing of effluents. In response to the threat of antimicrobial resistance (AMR), the company is committed to ensuring that its production waste is free of antibiotic residues.

     

    By upgrading to the fermentative and enzymatic process, production has become much cleaner with a significant decrease of the carbon footprint of the product. To this date, a reduction of more than 1.5 million tons of CO2 emissions, equivalent to over 350,000 airplane trips around the world, has been achieved.

     

    Frans Vlaar, Business Unit Director Europe America at DSP said: “Unlike today’s industry common practice, in which penicillin and chemical processes are used that require large volumes of solvents, our process is sustainable and environmentally-friendly, resulting in a higher 7-ADCA product quality and reducing the product carbon footprint. Last, but not least, I am proud that at DSP we take our responsibility in the fight against the global health and wealth threat of AMR. We need to take, use and especially make antibiotics responsibly to keep existing antibiotics effective, now and for generations to come.”

     

  • 27 October 2016

    DSM Sinochem Pharmaceuticals calls for urgent clean-up of antibiotics supply chain

    DSM Sinochem Pharmaceuticals calls for urgent clean-up of antibiotics supply chain

     

    On October 19th the campaigning organization Changing Markets published their report ‘Superbugs in the Supply Chain’, showing the occurrence of drug-resistant bacteria in water streams surrounding pharmaceutical manufacturing sites in India. The report traces a direct line from these irresponsible producers to patients in Europe and the United States, underlining the seriousness of environmental pollution from antibiotics production and its contribution to the global health and wealth threat of antimicrobial resistance (AMR). In response, DSM Sinochem Pharmaceuticals calls on all players in the supply chain to take their responsibility, and stop buying, using and selling irresponsibly produced antibiotics.

     

    The report reveals the results of an on-the-ground investigation by investigative agency Ecostorm which took place in June 2016 and subsequent analysis of water samples by the University of Cambridge. It found high levels of drug resistant bacteria at sites in three Indian cities Hyderabad, New Delhi and Chennai.

     

    As the report reveals, out of 34 sites tested, 16 were found to contain bacteria resistant to major classes of antibiotics, namely Cephalosporins, Fluoroquinolones and Carbapenems. Of the antibiotics manufacturing plants tested, three factories found to be severe antibiotic resistance hotspots. The report also traces a direct line from these manufacturers to market players in the United States and European countries like UK, France and Germany. Further supply chain links were also uncovered between polluting Chinese factories and Western markets.

     

    Substantial quantities of antibiotics released from polluting factories provide a perfect breeding ground for drug-resistant bacteria. These ‘superbugs’ are not only a serious danger to the nearby neighbourhoods and its people, but also contribute to the global spread of the staggering health and wealth threat of AMR. It is estimated by the WHO that if the rising peril of ‘superbugs’ is not defeated, 10 million lives every year could be lost by 2050.

     

    In the report a DSP subsidiary is mentioned in relation to Asiatic, one of the sites around which high levels of drug-resistant bacteria were found. Contrary to what was claimed falsely on their website, DSP is not a customer of Asiatic.

     

    DSP has long been vocal about the role of the industry in the fight against AMR. The company has regularly called on both the industry and the entire value chain to act responsibly and stop buying, using and selling irresponsibly produced antibiotics.

     

    As a leader in the sustainable production of antibiotics, DSP has already implemented the basic requirements for clean and sustainable antibiotics production at all sites, including:

    • using the cleanest production technology available for its products
    • operating dedicated wastewater treatment plants 24/7/365 as an integral part of the manufacturing process at all sites in combination with antimicrobial activity testing.

    Some other responsible antibiotics producers have done too.

     

    DSP has been one of the driving forces in the establishment of the pharmaceutical industry ‘Roadmap for Progress on Combating AMR’, signed by 13 leading pharmaceutical companies including DSP and presented at the UNGA on September 20th 2016. A key commitment in this Roadmap is to reduce the environmental impact from antibiotics production. This means all signatory companies will review their own manufacturing and supply chains and jointly establish a common framework for managing antibiotic discharge. The companies will work with various stakeholders to develop a practical mechanism to transparently demonstrate that supply chains meet the standards in the framework. Furthermore, the signatory companies will actively engage in establishing science-driven, risk-based targets for antibiotic release.

     

    DSP calls other antibiotic manufacturers – and especially the larger generic ones – to show leadership and join the UNGA Roadmap.

     

    Karl Rotthier, CEO of DSM Sinochem Pharmaceuticals at DSP, says: “The environmental impact of antibiotics manufacturing is firmly on the agenda of 13 leading pharmaceutical companies now. All pharmaceutical companies, both the innovators and generic producers, together with other stakeholders, must and can act fast to clean-up our supply chains. We all owe it to the world to produce essential life-saving antibiotics in the most responsible and sustainable way possible, and should conserve the effectiveness of existing antibiotics today, and for generations to come.”

     

    “The report on ‘Superbugs in the Supply Chain’ is another piece of evidence of the occurrence of high concentrations of drug-resistant bacteria in polluted waters around antibiotics manufacturing sites even though contamination could in theory also be caused by other sources”, says Lucas Wiarda, Head of the Sustainable Antibiotics Program at DSP. ”It is of crucial importance that academia with the support of e.g. the WHO increase their efforts and collect hard evidence fast of the devastating effect of irresponsible manufacturing, leading to AMR. As DSP we don't want to wait for this hard evidence, however. Therefore we call on all antibiotics producers, including generics manufacturers – also in India and China - to sign up for the UNGA Industry Roadmap.”

     

    * See also the ‘Bad Medicine’ Report by SumOfUs and studies by J. Larsson: “Effluent from drug manufacturers contains extremely high levels of pharmaceuticals.” Journal of Hazardous Materials, Volume 148, Issue 3, 30 September 2007, pp. 751–755; and “Pollution from drug manufacturing: review and perspectives”, Philosophical Transactions of The Royal Society B Biological Sciences 369(1656), November 2014.

     

     

  • 7 October 2016

    DSM Sinochem Pharmaceuticals Wins European Responsible Care Award For Work in Sustainable Antibiotics

    DSM Sinochem Pharmaceuticals Wins European Responsible Care Award For Work in Sustainable Antibiotics

     

    DSM Sinochem Pharmaceuticals (DSP) has won the prestigious CEFIC European Responsible Care Award in the Product Stewardship Category for its Sustainable Antibiotics program. The program is DSP’s own initiative to promote the responsible manufacturing and use of antibiotics.

     

    The European Chemical Industry Council (Cefic) runs the awards as part of its effort to strengthen the Responsible Care initiative, the global industry’s commitment to sustainability, and boost best-practice sharing across Europe.

     

    Antimicrobial resistance (AMR) is a major global health and wealth threat caused by the misuse and irresponsible manufacturing of antibiotics. DSP wants to play a leading role in the important global fight against AMR and particularly in reducing the environmental impact from the production of antibiotics. To this end, the company launched its Sustainable Antibiotics program in October 2014 and already put in place the basic measures to manufacture antibiotics responsibly: use of the cleanest production technology available for its products and the operation of dedicated wastewater treatment plants at all production sites in combination with antimicrobial activity testing.

     

    DSP has also taken on a high-profile campaigning role in the fight against AMR by calling on both the industry and the entire value chain to act responsibly and stop buying, using and selling irresponsibly produced antibiotics.

     

    The company was one of the driving forces in establishing the UN Industry Roadmap to combat AMR. This roadmap was presented at the UN General Assembly on 21 September in New York and signed by 13 leading pharmaceutical companies, including DSP. With the reduction of the environmental impact from antibiotics production as one of the four commitments in that Roadmap, this topic is firmly on the agenda of leading pharmaceutical companies now.

     

    DSP representatives were present at the assembly, and also at G20 side-events in Beijing and Shanghai, underlining the company’s approach to engage multiple stakeholders in the fight against AMR.

     

    Cefic’s President presented the European Responsible Care Award in the Product Stewardship Category to DSP on 7 October 2016 in Florence, Italy. Announcing the winners, the jury members praised DSP’s ‘well-rounded program with impact throughout the value chain’. They added that DSP is ‘very good in advocacy and highest in this category’.

     

    Lucas Wiarda, Head of the Sustainable Antibiotics Program of DSP said: “Principles of care and carefulness are at the core of our business. We make high quality medicines to cure illnesses and save lives. I simply cannot accept that irresponsible manufacturers pollute the environment with antibiotics, making people sick and even worse, contributing to the biggest health and wealth threat to mankind today: antimicrobial resistance. Therefore I am especially proud that our efforts to raise awareness for responsible manufacturing and our calls for pollution-free antibiotics are recognized and shared by Cefic and the chemicals industry, by granting DSP with the Responsible Care Award for Product Stewardship.”

     

    Karl Rotthier, CEO of DSP said: “We are honored to receive this prestigious award. Our Sustainable Antibiotics program has acted as a driver for sustainable change in our business and in the industry. With the Industry Roadmap now in place, pharmaceutical companies together with other stakeholders can and must act fast. I am convinced that in the coming years we will see antibiotics manufacturing companies move to sustainable and responsible suppliers. We must take, use and especially make antibiotics responsibly to conserve the effectiveness of existing antibiotics today, and for generations to come.”

     

  • 4 October 2016

    DSM Sinochem Pharmaceuticals offers Rosuvastatin API with CEP and Finished Dosage formulations using own API

    DSM Sinochem Pharmaceuticals offers Rosuvastatin API with CEP and Finished Dosage formulations using own API

     

     

    DSM Sinochem Pharmaceuticals (DSP) announced that it has been granted an update of the Certification of Suitability to the Monograph of the European Pharmacopoeia (CEP) for its generic Rosuvastatin Active Pharmaceutical Ingredient (API). DSP was among the first companies worldwide that started to offer a generic Rosuvastatin API under CEP. Rosuvastatin from DSP is produced at its own facility, using a unique fully backward integrated process. In addition to the Active Ingredient, DSP offers a comprehensive portfolio of finished dosage formulations using its own unique API.

     

    Statins are currently the most prescribed drug family globally for high cholesterol and cardiovascular disease and among the top selling drugs worldwide. Rosuvastatin is used for battling the number one cause of death worldwide: cardiovascular disease. The main applications for Rosuvastatin are hyperlipidemia and prevention of cardiovascular disease.

     

    After being the first company to receive a CEP for its Atorvastatin in 2012, DSP once again was a frontrunner with Rosuvastatin, receiving a CEP in early 2016 as one of the first three companies globally. In addition DSP has developed a comprehensive portfolio of Atorvastatin and Rosuvastatin finished dosage formulations using its in-house API. With this, DSP offers customers and marketing partners a one-stop-shop for their statin needs. Of course all formulations offer the known quality, reliability and sustainability benefits customers expect from DSP’s enzymatic APIs.

     

    With this update, DSP’s Rosuvastatin API is now produced at DSP’s own facility in Toansa, India, using a fully backward integrated production process. This involves a highly efficient enzymatic coupling step and uses one common building block intermediate for Rosuvastatin, Atorvastatin and Pitavastatin (under development). In line with DSP’s brand promise “Quality. Reliability. Sustainability.”, DSP’s Rosuvastatin offers customers superior performance in all three areas. The proprietary backward integrated process is protected by 10 patent families and offers customers independence of third party intermediate suppliers. Additional advantages include unrivalled product quality with an assay of >99%, large batch sizes of 200 kg, thereby significantly reducing Quality Assurance and testing costs, absence of hazardous chemicals such as butyl-lithium from production and a reduced carbon footprint of production by up to 35%.

     

    Receiving a CEP update confirms compliance of DSP’s Rosuvastatin to the European Pharmacopoeia. It will support DSP and its customers in more efficient registration and life cycle management of its products. The EDQM (Council of Europe) is the organization for Harmonization & Co-ordination of Standardization, Regulation & Quality Control of Pharmaceuticals and Pharmaceutical Care.

     

    Karl Rotthier, CEO of DSP said: “I am proud that DSM Sinochem Pharmaceuticals is among the first worldwide that will offer generic Rosuvastatin API and finished dosage formulations under CEP. This shows our dedication to excellence and our aspiration to continue to be an industry leader. As every one of our products, Rosuvastatin delivers superior performance on quality, reliability and sustainability when compared to the industry average. Building on our position in Atorvastatin, Rosuvastatin is an excellent addition to our product portfolio.”

     

    Frans Vlaar, Business Unit Director New APIs at DSP said: “Rosuvastatin is a proof point to our commitment to statins. Building on our excellent asset base in our factory in Toansa, India, we are proud to be able to offer customers both a high quality API and state-of-the-art finished dosage formulations. This also means our customers can continue to rely on us for high quality, high security of supply and unrivalled sustainability.”

     

    Amit Gandhi, Global Business Manager Statins at DSP said: “Thanks to the CEP, we can support our customers with fast and cost-efficient access to the EDQM member states, and facilitate optimal life cycle management. Our unique competencies together with being among the first worldwide that will offer generic Rosuvastatin under CEP will greatly help us to meet customer demand in the European market.”

     

  • 20 September 2016

    At UN General Assembly DSM Sinochem Pharmaceuticals calls for acceleration of fight against AMR

    At UN General Assembly, DSM Sinochem Pharmaceuticals calls for acceleration of fight against AMR due to environmental pollution resulting from antibiotics production

     

    Tomorrow, September 21, DSM Sinochem Pharmaceuticals (DSP), one of the world’s leading global generic antibiotics manufacturers, will take part in the United Nations General Assembly (UNGA) HighLevel Meeting on Antimicrobial Resistance (AMR) in New York. Ahead of the meeting, DSP and 12 other leading pharmaceutical companies presented a comprehensive roadmap laying out joint commitments to combat the threat of AMR. At the UNGA, Karl Rotthier, CEO of DSP, will address the Center for Disease Dynamics, Economics & Policy on AMR. He will argue that, now that the environmental impact of antibiotics manufacturing is firmly on the agenda of leading pharmaceutical companies, the industry can and should act quickly.

     

    UNGA recognizes need for urgent global action

    According to the World Health Organization (WHO), AMR is one of the biggest threats to global health. The mere fact that the UNGA has now for the first time placed it on the agenda of its High-Level Meeting also emphasizes the need for urgent global action. DSP will take part in the UNGA High-Level Meeting and other UNGA meetings as an industry partner, contributing its knowledge and experience to help the parties involved to find agreed ways of tackling AMR.

     

    New industry roadmap

    Today, ahead of the UNGA High-Level Meeting on AMR, DSP joined with 12 other leading pharmaceutical companies in presenting a new roadmap for combating AMR. It lays out four key commitments which these companies promise to deliver on by 2020. These commitments follow the principles agreed on in the Industry Declaration made at the 2016 World Economic Forum in Davos earlier this year. They also reflect the companies’ intention to continue to contribute proactively to address AMR. This unprecedented collaboration between these pharmaceutical companies marks a major milestone in the fight against AMR.

     

    Reducing the environmental impact of production

    DSP has been one of the driving forces in establishing this industry roadmap. As one of the signatories, it naturally underwrites all the commitments made, but it particularly supports one of the top priorities listed, namely the commitment to reduce the impact that the production of antibiotics has on the environment. Also, DSP believes that reducing the prevalence of substandard and counterfeit antibiotics in high-risk markets is one of the key areas in which the industry can and should take rapid action

     

    Key role of industry

    DSP has long been vocal about the role of the industry in the fight against AMR. The company has regularly called on both the industry and the entire value chain to act responsibly and stop buying, using and selling irresponsibly produced antibiotics. Irresponsible manufacturing is likely to accelerate AMR due to the uncontrolled release of antibiotics into the environment. In particular, water courses downstream of production facilities may contain significant concentrations of antimicrobial activity, and risk becoming breeding grounds for resistance. Several scientific studies have found concentrations of antibiotics in waterways that are 1,000 times higher than concentrations toxic to bacteria, as well as daily releases of a single antibiotic (ciprofloxacin) of up to 44kg*.

     

    Manufacturing standards and basic measures

    Given the significance of the issue, DSP seeks to become actively engaged in industry and multistakeholder working groups to reduce antibiotics pollution associated with manufacturing. More specifically, it seeks to set manufacturing standards to adequately manage antibiotic discharge and support the establishment of safe tolerance levels by independent technical experts. The company has already put in place the basic measures to manufacture antibiotics responsibly, with no unnecessary active antimicrobial discharge, by using the cleanest production technology available for its products and by operating dedicated wastewater treatment plants 24/7/365 as an integral part of the manufacturing process at all sites in combination with antimicrobial activity testing.

    “As a leading manufacturer of sustainable antibiotics, we’re excited about the ambitious joint industry commitments stated in the UNGA Roadmap,” says Karl Rotthier. “The actions proposed are important next steps in the fight against AMR. The environmental impact of antibiotics manufacturing is firmly on the agenda of leading pharmaceutical companies now, so we, together with other stakeholders, must and can act fast.”

     

    Even higher standards and transparency required

    DSP is fully committed to the goals stated in the roadmap. It believes that, as sustainable industry leaders, we should go beyond the roadmap commitments. Working towards defined minimum standards for managing antibiotic discharges and concentrations is not enough. In addition, well before 2020, mechanisms should be explored that will drive even higher standards and transparency throughout the supply chains by means of a “quality mark” or “labeling”.

    “We strongly believe that patients and buyers of generic antibiotics should have the right to choose highquality antibiotics from non-polluting sources,” emphasizes Lucas Wiarda, Global Marketing Director & Head of the Sustainable Antibiotics Program at DSP. “To conserve the effectiveness of existing antibiotics today, and for generations to come, we have to take, use and especially make antibiotics responsibly.”

     

    *studies by J. Larsson: “Effluent from drug manufacturers contains extremely high levels of pharmaceuticals.” Journal of Hazardous Materials, Volume 148, Issue 3, 30 September 2007, pp. 751–755; and “Pollution from drug manufacturing: review and perspectives”, Philosophical Transactions of The Royal Society B Biological Sciences 369(1656), November 2014.

     

    ABOUT ANTIMICROBIAL RESISTANCE

    Antimicrobial resistance (AMR) is the natural process by which bacteria and other microbes develop resistance to the drugs commonly used to treat infections. Antimicrobials include antibiotics (which act only on bacteria), antivirals, antiparasitics and antifungals. In 2014, the independent Review on AMR, chaired by the economist Lord Jim O’Neill, estimated that without effective global action, the rise of AMR could claim 10 million lives globally each year by 2050, and result in a cumulative loss in global output of USD 100 trillion. The growth of resistance to antibiotics represents a particularly serious threat to modern healthcare. We rely on effective antibiotics to treat common infections and to ensure that other medical procedures (such as surgery or cancer chemotherapy) remain safe and routine. However, a combination of scientific, regulatory and commercial challenges has meant that the discovery of new antibiotics in recent decades has failed to keep pace with the rise of antibiotic-resistant infections. Meanwhile, we face the dual problem of pervasive over-use and misuse of antibiotics and other antimicrobials in animals and humans in most parts of the world even though there is increasing evidence that antibiotic pollution associated with manufacturing contributes to AMR, exacerbating the development of drug resistance, while there is a lack of affordable access to antimicrobials in others.

     

    ABOUT THE INDUSTRY ROADMAP FOR PROGRESS ON COMBATING AMR

    On September 20, ahead of the 2016 United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR) in New York, 13 leading pharmaceutical companies presented a new roadmap that lays out four key commitments they promise to deliver by 2020 to reduce AMR. The roadmap represents a major milestone following the Declaration signed in January 2016 at the World Economic Forum by more than 100 companies and trade associations . In presenting this roadmap, the signatory companies firmly demonstrate their shared ambition to overcome the staggering threat AMR represents for our society, economies, and citizens. They are committed to working to reduce the development of AMR, to improve access to high-quality antibiotics, vaccines, and diagnostics, to invest in R&D, and to collaborate with governments and stakeholders to sustain those investments.

     

    ABOUT THE DAVOS DECLARATION

    On January 21, 2016, the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance was launched during the World Economic Forum in Davos, Switzerland. The Declaration was drafted, agreed and signed by 85 companies and 9 industry associations from across the global pharmaceutical, diagnostics and biotechnology industries. By April 1, 2016, a total of 98 companies and 11 industry associations in 21 countries had signed the Declaration. In the Declaration, signatory companies call on governments to work with them to develop new and alternative market structures that provide more dependable and sustainable market models for antibiotics, and to commit the funds needed to implement them. These mechanisms are needed to provide appropriate incentives (coupled with safeguards to support antibiotic conservation) for companies to invest in R&D to overcome the formidable technical and scientific challenges of antibiotic discovery and development. These include mechanisms to ensure that, where appropriate, the pricing of antibiotics more adequately reflects the benefits they bring, as well as novel payment models that reduce the link between the profitability of an antibiotic and the volume sold. An integral part of these models is a reduced need for promotional activity by companies.

     

  • 24 May 2016

    DSP welcomes the clear recommendations of the AMR Review

    DSM Sinochem Pharmaceuticals supports fight against superbugs and welcomes the clear recommendations of the AMR Review

     

    DSM Sinochem Pharmaceuticals (DSP) welcomes the final report of Lord O’Neill’s global AMR Review, which lists concrete interventions to fight antimicrobial resistance (AMR) and the drug resistant superbugs it creates. DSP fully supports these measures. Guided by its brand promise “Quality. Reliability. Sustainability.”, DSP has been advocating for more transparency in the value chain and to stop irresponsible production of antibiotics. In line with the AMR Review recommendations, DSP is promoting the use of the best and cleanest available technology, dedicated waste water treatment plants and antimicrobial activity testing, to ensure clean and high quality production.

     

    Lord Jim O’Neill’s global Review on AMR sets out its final recommendations, providing a comprehensive action plan for the world to prevent drug-resistant infections and defeat the rising threat of superbugs – something that could cost 10 million lives a year by 2050, the equivalent of 1 person every 3 seconds, and more than cancer kills today.

     

    DSP is glad to see that the AMR Review addresses the role of irresponsible antibiotics production and unnecessary pollution; something that has long been missing in the public debate. The irresponsible manufacturing of antibiotics forms a particular risk for the acceleration of antimicrobial resistance (AMR) via the uncontrolled release of antibiotics into the environment. Quantities of concentrated active compounds disposed via this route, particularly water courses downstream of production facilities, can show marked concentrations of antimicrobial activity and risk becoming breeding grounds for resistance.

     

    DSP cannot accept that a life-saving drug may become less effective. It therefore demands that the industry to stop buying, making and selling irresponsibly made antibiotics. DSP very much welcomes the recommendation of the AMR Review that stipulate using the best available technology, dedicated waste water treatment plants and the execution of antimicrobial activity tests to ensure returned water is truly clean and safe. Measures that some responsible antibiotics producers, including DSP, have already implemented at their sites.

     

    DSP also stipulates that in the short run, an industry label for responsible use and manufacturing of antibiotics can help to take quick and effective action, much like we have seen in other industries. Ultimately, such measures should become part of existing frameworks such as Good Manufacturing Practices (GMP).

     

    Karl Rotthier, CEO of DSM Sinochem Pharmaceuticals said: “In 2013, we were the only company raising the issue of pollution from antibiotics production. I am glad to see that today this topic has become part of the global debate! DSP is committed to following the recommendations of Lord O’Neill’s Global Review on AMR and will continue to advocate for responsible and clean production. We all owe it to the world to produce these essential life-saving medicines in the most responsible and sustainable way possible.

     

    Lucas Wiarda, Global Marketing Director and Head of the Sustainable Antibiotics Program of DSM Sinochem Pharmaceuticals said: “I am very happy to see pharma pollution getting the attention it needs. This is the area where we as the industry must take urgent action and can make a difference in short time. At the same time it is imperative that we continue to address the global issue of AMR in line with the ‘one-health‘ approach, addressing human and veterinary use but also pollution from production. The AMR Review, led by Lord Jim O’Neill, quickly became a unique internationally respected institute. Their reports have helped to raise awareness for AMR in the public, while their proposed interventions from an opportunity for the entire industry to take responsibility, define solutions and ensure a positive contribution to society. I am hopeful that their recommendations will be quickly adapted by politics, the public at large and the industry.

     

    DSP has long been vocal about the role of the industry in antibiotic resistance and the need to use the cleanest production technology and dedicated waste water treatment plants in combination with antibiotic water testing. These basic requirements for clean and sustainable antibiotics production are implemented at all DSP sites.

     

    These efforts are shared in more detail in the annual Sustainability Report of DSP, available from the company website www.dsm-sinochem.com.

     

    AMR: a global health threat

    Antimicrobial Resistance (AMR) is one of the biggest health threats facing mankind, and the imperative for action is growing at both an individual and a global political level. Progress on both of these fronts is needed in order to tackle this threat, and this cannot be limited to action on human and agricultural use. It must also include action to ensure that manufacturing practices are improved and the quantities of APIs reaching the environment through waste are reduced. The human and economic cost of inaction could mean up to 10 mio. deaths per year from AMR alone and a cumulative hit to the world economy of 100 trillion USD, if we do not curb resistance and find long-term solutions to producing, using and disposing of antibiotics responsibly.

     

     

    --

    DSM Sinochem Pharmaceuticals is the global leader in Sustainable Antibiotics and next generation statins. Our employees worldwide work together to deliver cutting edge generics solutions that help to keep customers ahead of the competition.

    Headquartered in Singapore, the group has operations in China, India, Egypt, the Netherlands, Spain, the US and Mexico.

     

    Please visit www.dsm-sinochem.com for more information or contact

    DSM Sinochem Pharmaceuticals

    Global Head of Branding & Communications Mansur Gharabaghi

    E-Mail: info@dsm-sinochem.com

     

  • 24 May 2016

    DSP is one of three finalists for the Dutch VNCI Responsible Care Award

    Via our Sustainable Antibiotics Program we were one of three finalists for the Dutch Responsible Care Award.

     

    DSM Sinochem Pharmaceuticals  Sustainable Antibiotics Program aims to address the role of irresponsible antibiotics manufacturing practices in the global spread of Antibiotic Resistance, on top of the misuse of antibiotics by humans and agriculture. We must make antibiotics responsibly to keep them effective for us and generations to come. The industry should stop buying, making and selling irresponsibly made antibiotics.

     

    Ultimately the first place went to SABIC - congratulations! We remain confident that we are doing the right things in our Sustainable Antibiotics program, something we also saw confirmed as the winner of the majority of public votes.

     

  • 1 January 2011

    Sinochem acquires 50% of DSM Anti-Infectives to form DSM Sinochem Pharmaceuticals6

  • 28 April 2016

    DSP appoints Anurag Roy as Business Unit Director AMEA

    DSM Sinochem Pharmaceuticals appoints Anurag Roy as its new Business Unit Director Asia Pacific, Middle East and Africa

     

    DSM Sinochem Pharmaceuticals, the global leader in sustainable antibiotics, next generation statins and anti-fungals, has appointed Anurag Roy as its new Business Unit Director for Asia Pacific, Middle East and Africa. Mr. Anurag will also be the Global Product Owner New API.

     

    Anurag is a seasoned chemical, pharmaceutical and life sciences industry professional, having acquired a wealth of business and product management experience during his 17 years of strategic, operational and financial leadership. He has an excellent track record in uniquely challenging global and indigenous business environments, specifically in forging strategic partnerships with innovators, driving organizational profit and establishing credibility. Anurag has previously held senior management positions at various companies, most recently as Vice President, Custom Pharmaceuticals Services, Dr. Reddy’s Laboratories (DRL). He also has experience of escalating business growth at three US-based companies, BASE-SAF, a chemical manufacturer; ORC International, a market research consultancy and Frost and Sullivan, the global growth consulting firm. His areas of expertise have, therefore, encompassed driving business, strategic marketing, and motivating cross functional global teams for peak performance, mergers, acquisitions and new ventures.

     

    Anurag holds an MBA from Columbia Business School, New York, USA. He has authored several articles which have appeared in leading publications such as LA Times, Chemical Week, Modern Plastics, International Journal of Polymer Sciences, Economic Times & Business India. He has also presented scientific papers and has been a key spokesperson at several international conferences.

     

  • 11 March 2016

    DCAT Week 2016 Press Release on Sustainable Antibiotics

    DSM Sinochem Pharmaceuticals will actively address antimicrobial resistance during DCAT Week 2016.

     

    DSM Sinochem Pharmaceuticals (DSP), a leading producer of sustainable antibiotics, has declared it will actively engage with its peers to identify solutions to the global health threat of antimicrobial resistance (AMR) from the industry’s perspective. DSP welcomes that an increasing number of pharmaceutical companies and their suppliers are starting to join forces and together address the role of irresponsible and polluting antibiotic manufacturing in accelerating AMR. This is an encouraging first step but continued industry attention and urgent action is required, says DSP.

  • 2 November 2015

    Sustainability Report 2014 Published

    DSM Sinochem Pharmaceuticals (DSP) issues the Sustainability Report 2014, inspired by the GRI framework. The Report gives an overview of DSP's business and sustainability performance and DSP's efforts on Sustainable Antibiotics.

     

    Karl Rotthier, CEO of DSP, highlighted the importance of antibiotics for mankind and our responsibility to ensure that these life-saving drugs remain effective and are thus produced responsibly.

  • 16 June 2015

    ‘Responsible waste management is key to curbing increasing antimicrobial resistance’

    Following the Global Health Summit in Uppsala (Sweden) on 2-3 June, 2015, DSM Sinochem Pharmaceuticals (DSP) pledged its commitment to the WHO’s ‘Call to Action’ on antimicrobial resistance issued at the Summit. One of the biggest opportunities to maintain the effectiveness and availability of antibiotics is responsible waste management, to date a highly undervalued dimension in the debate around resistance. DSP promised to use its expertise and influence in this area to help curb antimicrobial resistance or AMR.

     

  • 21 January 2015

    DSP granted updated CEP for Atorvastatin API from its new statins facility in India

    DSM Sinochem Pharmaceuticals today announced that it has completed construction of a world-class statins plant in Toansa, India. Production of atorvastatin started in the second half of 2014, using DSP’s proprietary enzymatic (bio)technology route. The new plant is included in the updated CEP (CEP 2010-366, revision 2) for Atorvastatin Calcium from DSP.

     

    The new facility was included in DSP’s existing CEP within the shortest possible time, on first submission and without questions from regulators; proof of DSP’s excellent regulatory knowledge. The plant will help DSP meet strong demand for its high quality atorvastatin active pharmaceutical ingredient (API) and fuels further expansion of DSP’s API portfolio. Receiving a CEP confirms compliance of DSP’s Atorvastatin from its Toansa plant to the European Pharmacopeia. It will support DSP and its customers in efficient registration and life cycle management of their products.

     

    In the course of 2015, DSP aims to also service rosuvastatin API from the Toansa facility. Rosuvastatin and atorvastatin from DSP are based on the same unique enzymatic (bio)technology platform, which will also help DSP to further expand its statins portfolio in the future.

    Atorvastatin is currently the most prescribed drug globally for high cholesterol and cardiovascular disease and one of the top selling drugs worldwide. It is a member of the drug class known as statins, used for battling the number one cause of death worldwide: cardiovascular disease.

     

    Frans Vlaar, Director of the unit new APIs at DSP said: “By implementing our enzymatic technology in our own world-class plant, we are able to produce material with the highest purity and compliance levels in the industry, with largest capacity and batch sizes and most importantly, lowest environmental footprint.

  • 26 November 2014

    DSP publishes first ever Sustainability Review for 2013

    DSM Sinochem Pharmaceuticals (DSP) issues the 2013 Sustainability Review, inspired by the GRI framework. The Review gives an overview of DSP's business, sustainability strategy and environmental performance.

     

    DSM Sinochem Pharmaceuticals (DSP) issues the 2013 Sustainability Review, inspired by the GRI framework. The Review gives an overview of DSP's business, sustainability strategy and environmental performance.

     

    Karl Rotthier, DSP’s President, highlighted the importance of sustainability as a core value and a key business driver for DSP.

  • 25 November 2014

    Press Release for Antibiotic Awareness Week 2014

    Antibiotic Awareness Week 2014

     

    Antibiotic resistance threatens future of modern medicine, warns DSP President. The world risks “sleepwalking” towards the end of modern medicine unless urgent action is taken to halt the rise of antibiotic resistance, DSM Sinochem Pharmaceuticals (DSP) warned today.

     

    Karl Rotthier, DSP’s President, praised the role of Antibiotic Awareness Week and said a concerted global effort was needed to stem the tide of a “post-antibiotic era”, when minor ailments once again become deadly. He argued that overuse and misuse of antibiotics was one of the key contributors to antimicrobial resistance (AMR) but that the pharmaceutical industry must also accept greater responsibility for driving the solution.

     

    Mr Rotthier said the responsibility was on everyone from patients and doctors to governments and pharmaceutical companies to take immediate steps to ensure that the “legacy of antibiotics as a life-saving medicine is not squandered”. “It’s important that Antibiotic Awareness Week is more than a seven-day conversation on these challenges but instead a catalyst for long-lasting commitments from patients and doctors to governments and manufacturers to fight AMR.” Mr Rotthier said that producers must “step up to the plate” and ensure that we adopt the cleanest, most rigorous and sustainable methods available to minimize the environmental impact of producing life-saving medicines and do our utmost to curb the advancement of AMR.

  • 7 October 2014

    DSP at the CPhI Worldwide in Paris

    DSM Sinochem Pharmaceuticals at the CPhI Worldwide in Paris

     

    DSM Sinochem Pharmaceuticals had a combined booth with DSM Nutritional Products at this year's CPhI Worldwide trade show in Paris. DSP unveiled its new generation of enzymatically produced eco-friendly super-statins Atorvastatin and Rosuvastatin.

     

    At the CPhI Worldwide in Paris DSM Sinochem Pharmaceuticals (DSP) unveiled a new generation of eco-friendly super-statins after developing a pioneering production method to maximize purity and radically cut the environmental impact of making these important medicines.

    Statin are currently the most prescribed drug class globally for high cholesterol and cardiovascular disease and one of the top selling drugs worldwide. They are used for battling the number one cause of death worldwide: cardiovascular disease. Statins are proven to lower LDL (the 'bad' cholesterol) by up to 60% in combination with a healthy diet and exercise.

    DSP’s unique technology leads to a carbon footprint 35% lower than traditional production methods today and will improve further: less waste, and unrivalled purity - as hardly any solvents end up in the final product. The superior quality also enhances the stability and allows formulators to dose more accurately.

    DSP pioneered enzymatic API production in the late 90’s, which led to the well known range of PureActives™ antibiotics.

    Read the full press release.

  • 6 October 2014

    Antibiotics industry must embrace sustainability, urges DSP chief

    The legacy of antibiotics is at “serious risk” and the pharmaceutical industry must contribute to the solution by embracing sustainability, DSM Sinochem Pharmaceuticals (DSP) has warned

     

    Antibiotics industry must embrace sustainability, urges DSP chief

     

    Karl Rotthier, DSP’s President, said the “most important medicine known to mankind” faced a bleak future amid the rise of antimicrobial resistance (AMR), lowered production standards, and pollution by irresponsible low cost manufacturers.

  • 24 June 2014

    Code Name BACINOL

    Dutch microbiologists, working in secret during the last months of WWII, developed procedures for making penicillin

     

    When Germans occupied the Netherlands during World War II, a team at NG&SF secretly isolated, characterized, and produced penicillin—working under the code name 'Bacinol.' Although 'penicillin' now refers to a familiar group of β-lactam antibiotics, it initially was used to describe 'mold juice' with antibacterial properties—in essence, a crude filtrate that contained one or more beta-lactam metabolites and their impurities.

     

    Read the full story

  • 24 June 2014

    Sustainability Summit 2014

    The Dutch Embassy in India and DSP India joined hands and hosted the Sustainability Summit 2014

     

    The Dutch Embassy in India and DSM Sinochem Pharmaceuticals (DSP) joined hands and hosted the Sustainability Summit 2014. The summit focused on the need for sustainable solutions for India and ways of collaboration between the Dutch embassy, Punjab government and DSP to address the challenge of sustainable development. The summit was attended by representatives of the Punjab government, the Embassy of the Netherlands, DSM India and DSP.

  • 7 March 2013

    DSP to launch Puriclor® (cefaclor), the newest member of the PureActives®

    DSM Sinochem Pharmaceuticals (DSP) adds Puriclor® (cefaclor) to its DSMPureActivesTM range of unique enzymatically produced active pharmaceutical ingredients (API). Puriclor®, a second generation cephalosporin antibiotic, is used to treat bacterial infections such as pneumonia as well as ear, throat and urinary tract infections.

  • 25 September 2012

    PUREEVENT: celebrating 10 Years of Purimox®

    On September 25, 2002, the first batch of Purimox® was produced in Almería, Spain. Our proven enzymatic technology has been applied for other molecules in our portfolio ever since, making DSM Sinochem Pharmaceuticals the most environmentally friendly producer of antibiotics in the world.

  • 14 September 2012

    DSM Sinochem Pharmaceuticals granted a CEP for Atorvastatin

    DSM Sinochem Pharmaceuticals today announced that it has been granted a Certification of Suitability to the Monograph of the European Pharmacopoeia (CEP) for its generic Atorvastatin, the global number one drug for cardiovascular disease. Using a unique fully backward integrated process DSM Sinochem Pharmaceuticals is the first company worldwide that will offer generic Atorvastatin Active Ingredients under CEP.

  • 21 June 2012

    DSM Sinochem Pharmaceuticals opens new 6-APA intermediate plant in China

    In the presence of the governor of Jilin province, Mr. Wang Rulin, the opening ceremony of DSM Sinochem Pharmaceuticals’ newest intermediate plant was celebrated in YuShu, China. The new plant will produce the beta-lactam intermediate 6-APA (6-Aminopenicillanic Acid) for global markets. 6-APA is the key intermediate for the production of SSPs (Semi-Synthetic Penicillins), which are used worldwide to combat infectious disease.

  • 12 December 2011

    DSM Sinochem Pharmaceuticals to build a Multi-Product Plant in China

    The groundbreaking ceremony for the construction of DSM Sinochem Pharmaceuticals’ newest production facility has taken place on December 9th, 2011 in Zibo’s High & New Technology Development Zone. The new plant will focus on the production and development of new Semi-Synthetic Cephalosporins (SSC) using proprietary biotechnology.

  • 1 January 2011

    Sinochem acquires 50% of DSM Anti-Infectives to form DSM Sinochem Pharmaceuticals

    In a joint venture Sinochem Group acquires 50% of DSM Anti-Infectives from Royal DSM to form DSM Sinochem Pharmaceuticals.

Copyright © 2017 DSM Sinochem Pharmaceuticals

Join the conversation

Follow us on Facebook Follow us on Twitter Follow us on LinkedIn
DSM Sinochem Pharmaceuticals logo